SMARCA4 and cancer: Consequently, SMARCA4/2-deficient cancer cells and tumors are highly sensitive to clinically available inhibitors targeting OXPHOS or glutamine metabolism as well as supplementation of alanine that competes with glutamine import, providing multiple potential effective treatment options for targeting these hard-to-treat malignancies.